Bel Fuse director granted 1,030 Class B shares

Smith Rita reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Smith Rita reported acquisition or exercise transactions in this Form 4 filing.

BEL FUSE INC director Dr. Rita Smith received a grant of 1,030 restricted shares of Class B Common Stock as compensation. These restricted shares vest in stages: 343 shares on March 15, 2027, 343 shares on March 15, 2028, and 344 shares on March 15, 2029. After this award, Dr. Smith directly holds a total of 5,827 Class B shares. The grant is a stock-based award rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 1,030 shares

Grant/Award 1 txn

Insider Smith Rita

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class B Common Stock	1,030	$0.00	$0.00

Holdings After Transaction: Class B Common Stock — 5,827 shares (Direct)

Footnotes (1)

F1. Dr. Smith was granted 1,030 restricted shares of Class B Common Stock on March 15, 2026. The restricted shares vest as follows: 343 shares vest as of March 15, 2027; 343 shares vest as of March 15, 2028; and 344 shares vest as of March 15, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Bel Fuse (BELFA) Form 4 report for Dr. Rita Smith?

The Form 4 reports that director Dr. Rita Smith received a grant of 1,030 restricted shares of Bel Fuse Class B Common Stock, increasing her direct holdings to 5,827 shares. This is a stock-based compensation award, not an open-market share purchase.

How many Bel Fuse (BELFA) shares were granted to Dr. Rita Smith?

Dr. Rita Smith was granted 1,030 restricted shares of Bel Fuse Class B Common Stock. This award is recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market transaction, and raises her direct Class B share ownership to 5,827 shares.

What is the vesting schedule of Dr. Rita Smith’s Bel Fuse (BELFA) restricted shares?

The 1,030 restricted Class B shares granted to Dr. Rita Smith vest in three annual installments: 343 shares on March 15, 2027, another 343 shares on March 15, 2028, and the remaining 344 shares on March 15, 2029, assuming continued service through those dates.

Is Dr. Rita Smith’s Bel Fuse (BELFA) stock award an open-market purchase?

No, the transaction is a compensation grant of restricted Class B Common Stock at a stated price of $0.00 per share. It reflects stock-based director compensation rather than an open-market buy, and the award vests over three years from March 2027 through March 2029.

How many Bel Fuse (BELFA) shares does Dr. Rita Smith own after this Form 4 transaction?

Following the grant of 1,030 restricted Class B shares, Dr. Rita Smith directly owns 5,827 shares of Bel Fuse Class B Common Stock. This total includes the newly granted restricted shares, which will vest in three installments between March 2027 and March 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/17/2026 - 04:46 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Rita

(Last)

(First)

(Middle)

C/O BEL FUSE INC.

300 EXECUTIVE DRIVE, SUITE 300

(Street)

WEST ORANGE

07052

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BEL FUSE INC /NJ [ BELFB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B Common Stock	03/15/2026		A		1,030⁽¹⁾	A	$0	5,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Dr. Smith was granted 1,030 restricted shares of Class B Common Stock on March 15, 2026. The restricted shares vest as follows: 343 shares vest as of March 15, 2027; 343 shares vest as of March 15, 2028; and 344 shares vest as of March 15, 2029.

	/s/ Lynn Hutkin	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR